1. Home
  2. MEIP vs BRN Comparison

MEIP vs BRN Comparison

Compare MEIP & BRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • BRN
  • Stock Information
  • Founded
  • MEIP 2000
  • BRN 1956
  • Country
  • MEIP United States
  • BRN United States
  • Employees
  • MEIP N/A
  • BRN N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • BRN Oil & Gas Production
  • Sector
  • MEIP Health Care
  • BRN Energy
  • Exchange
  • MEIP Nasdaq
  • BRN Nasdaq
  • Market Cap
  • MEIP 13.3M
  • BRN 13.9M
  • IPO Year
  • MEIP 2003
  • BRN N/A
  • Fundamental
  • Price
  • MEIP $2.53
  • BRN $1.15
  • Analyst Decision
  • MEIP Hold
  • BRN
  • Analyst Count
  • MEIP 1
  • BRN 0
  • Target Price
  • MEIP N/A
  • BRN N/A
  • AVG Volume (30 Days)
  • MEIP 21.5K
  • BRN 1.4M
  • Earning Date
  • MEIP 05-13-2025
  • BRN 08-12-2025
  • Dividend Yield
  • MEIP N/A
  • BRN N/A
  • EPS Growth
  • MEIP N/A
  • BRN N/A
  • EPS
  • MEIP N/A
  • BRN N/A
  • Revenue
  • MEIP N/A
  • BRN $19,387,000.00
  • Revenue This Year
  • MEIP N/A
  • BRN N/A
  • Revenue Next Year
  • MEIP N/A
  • BRN N/A
  • P/E Ratio
  • MEIP N/A
  • BRN N/A
  • Revenue Growth
  • MEIP 33.76
  • BRN N/A
  • 52 Week Low
  • MEIP $1.46
  • BRN $1.13
  • 52 Week High
  • MEIP $4.10
  • BRN $2.53
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 78.43
  • BRN 43.48
  • Support Level
  • MEIP $2.21
  • BRN $1.16
  • Resistance Level
  • MEIP $2.95
  • BRN $1.58
  • Average True Range (ATR)
  • MEIP 0.15
  • BRN 0.26
  • MACD
  • MEIP 0.05
  • BRN -0.03
  • Stochastic Oscillator
  • MEIP 81.48
  • BRN 4.46

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About BRN Barnwell Industries Inc.

Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.

Share on Social Networks: